Advanced BCC is a serious disease with historically limited treatment options

  • BCC is the most common cancer, with >2 million new cases diagnosed annually in the US1,2
  • While most patients with early-stage BCC are cured with complete surgical excision and/or radiation, ≈20K cases progress to advanced BCC each year1-4
  • Some of these advanced patients are no longer candidates for curative surgery and/or curative radiation1,5
  • HHIs are approved for patients with advanced BCC who are no longer candidates for curative surgery and/or curative radiation6,7
  • There is a significant unmet need for patients who discontinue HHI therapy or for whom HHI therapy is inappropriate5-10

BCC=basal cell carcinoma; HHI=hedgehog inhibitor.